The Online Investor
Caladrius Biosciences Inc (NBS)

NeoStem is engaged in the development of proprietary cell therapy products, and operating a contract development and manufacturing organization providing services in the regenerative medicine industry. Co. is developing therapies to address ischemia through its CD34 Cell Program. AMR-001 is Co.'s product candidate in this program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack). Another platform technology Co. is developing uses T Regulatory Cells to treat diseases caused by imbalances in the immune system. In addition, pre-clinical assets include Co.'s VSEL™ (Very Small Embryonic Like) Technology regenerative medicine platform.
Company Name: 
Caladrius Biosciences Inc
Website: 
www.neostem.com
Sector: 
Biotechnology
Quotes delayed 20 minutes

Email EnvelopeFree NBS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
82nd percentile
(ranked higher than approx. 82% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Caladrius Biosciences Inc (NBS) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.